Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8324157 | NOVO | Preparation comprising insulin, nicotinamide and an amino acid |
Jun, 2030
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Dec 19, 2022 |
New Product(NP) | Sep 29, 2020 |
M(M-247) | Oct 21, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(a month from now) | |
US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 6 months from now) | |
US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
US8324157 | NOVO | Preparation comprising insulin, nicotinamide and an amino acid |
Jun, 2030
(6 years from now) | |
US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Dec 19, 2022 |
New Product(NP) | Sep 29, 2020 |
M(M-247) | Oct 21, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6861409 | NOVO | Growth hormone secretagogues |
Aug, 2022
(1 year, 8 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8192719 | NOVO | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Oct, 2027
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-170) | Dec 20, 2024 |
New Chemical Entity Exclusivity(NCE) | Dec 20, 2022 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: 20 December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION;ORAL
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 10 months from now) | |
US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(a month from now) | |
US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(1 year, 3 months from now) | |
US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 6 months from now) | |
US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 6 months from now) | |
US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-185) | Mar 28, 2025 |
New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
New Indication(I-822) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; An adjunct to diet and exercise to improve glycemic control in...
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10351854 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
US10738311 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
US11359203 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
US11053502 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
US11661604 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(14 years from now) | |
US11286488 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-443) | Sep 29, 2030 |
New Chemical Entity Exclusivity(NCE) | Sep 29, 2028 |
Drugs and Companies using NEDOSIRAN SODIUM ingredient
NCE-1 date: 30 September, 2027
Market Authorisation Date: 29 September, 2023
Treatment: Method of treating primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION;INJECTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 10 months from now) | |
US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10086047 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(7 years from now) | |
US9278123 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(7 years from now) | |
US10960052 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
Dec, 2031
(7 years from now) | |
US11382957 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(7 years from now) | |
US11759501 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
US10933120 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
US11759502 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
US11759503 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
US10278923 | NOVO | Oral dosing of GLP-1 compounds |
May, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 20, 2022 |
New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7615532 | NOVO | Insulin derivatives |
Jun, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5866538 | NOVO | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(a month from now) | |
US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 6 months from now) | |
US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
US9884094 | NOVO | Method of treating diabetes mellitus |
May, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Dec 16, 2019 |
New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 25 September, 2015
Treatment: Method of improving glycemic control in patients with diabetes mellitus by administering a mixture of insulin degludec and insulin aspart during or around the time of the largest meal of the day
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7235627 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2017
(6 years ago) | |
US6458924 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2017
(6 years ago) | |
US6268343 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2022
(1 year, 7 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8846618 | NOVO | Stable formulation of modified GLP-1 |
Jun, 2022
(1 year, 9 months ago) | |
US6899699 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 9 months ago) | |
US8672898 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 9 months ago) | |
US9486588 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 9 months ago) | |
US8846618 (Pediatric) | NOVO | Stable formulation of modified GLP-1 |
Dec, 2022
(1 year, 3 months ago) | |
US6268343 (Pediatric) | NOVO | Derivatives of GLP-1 analogs |
Feb, 2023
(1 year, 1 month ago) | |
US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
US8579869 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(3 months ago) | |
US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(a month from now) | |
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(7 months from now) | |
US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(1 year, 3 months from now) | |
US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 6 months from now) | |
US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 6 months from now) | |
US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US8114833 (Pediatric) | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(1 year, 9 months from now) | |
US8684969 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(2 years from now) | |
US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US9616180 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(2 years from now) | |
US9861757 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(2 years from now) | |
US9108002 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(2 years from now) | |
USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
US8920383 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
US10220155 (Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(2 years from now) | |
US9775953 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
USRE46363 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(2 years from now) | |
US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
US9687611 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(3 years from now) | |
US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
US9457154 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(3 years from now) | |
US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
US9132239 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(8 years from now) | |
US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(12 years from now) | |
US9968659 (Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Dec 04, 2023 |
New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
New Product(NP) | Jan 25, 2017 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7615532 | NOVO | Insulin derivatives |
Jun, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(a month from now) | |
US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 6 months from now) | |
US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Dec 16, 2019 |
New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 10 months from now) | |
US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9764003 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(9 years from now) | |
US11752198 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(14 years from now) | |
US10888605 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(14 years from now) | |
US11318191 | NOVO | GLP-1 compositions and uses thereof |
Feb, 2041
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 04, 2024 |
New Dosing Schedule(D-190) | Jul 21, 2026 |
New Indication(I-935) | Mar 08, 2027 |
New Patient Population(NPP) | Dec 23, 2025 |
New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management according to a dose escalation schedule; Method for weight management
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6458924 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2017
(6 years ago) | |
US7235627 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2017
(6 years ago) | |
US8846618 | NOVO | Stable formulation of modified GLP-1 |
Jun, 2022
(1 year, 9 months ago) | |
US6268343 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2022
(1 year, 7 months ago) | |
US7615532 | NOVO | Insulin derivatives |
Jun, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
US9486588 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 9 months ago) | |
US8672898 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 9 months ago) | |
US6899699 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 9 months ago) | |
US8846618 (Pediatric) | NOVO | Stable formulation of modified GLP-1 |
Dec, 2022
(1 year, 3 months ago) | |
US6268343 (Pediatric) | NOVO | Derivatives of GLP-1 analogs |
Feb, 2023
(1 year, 1 month ago) | |
US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
US8579869 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(3 months ago) | |
US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(a month from now) | |
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(7 months from now) | |
US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 6 months from now) | |
US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 9 months from now) | |
US8684969 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(2 years from now) | |
US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
US9108002 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(2 years from now) | |
US9861757 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(2 years from now) | |
US9616180 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(2 years from now) | |
US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
US10220155 (Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(2 years from now) | |
US8920383 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
US9775953 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(2 years from now) | |
USRE46363 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(2 years from now) | |
US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
US9687611 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(3 years from now) | |
US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
US9457154 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(3 years from now) | |
US8937042 | NOVO | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide |
May, 2029
(5 years from now) | |
US8937042 (Pediatric) | NOVO | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide |
Nov, 2029
(5 years from now) | |
US7615532 (Pediatric) | NOVO | Insulin derivatives |
Dec, 2029
(5 years from now) | |
US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
US9132239 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-242) | Aug 08, 2022 |
New Combination(NC) | Nov 21, 2019 |
New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS